The $1m funding will support later stage clinical trial of inhaled formulation of levodopa that is developed as an adjunct PRN therapy offering relief from intermittent debilitating motor fluctuations (OFF) impacting a majority of Parkinson’s disease patients.
A Phase 2a trial demonstrated rapid and durable improvement in motor function in study participants administered with CVT- 301 in the OFF state.
Civitas founder and chief scientific officer Rick Batyckyv said, "We receive consistent feedback that our simple product configuration is uniquely suited for this patient population and this furthers our confidence that CVT-301 has the potential to provide a transformative benefit to those suffering from this devastating disease."
MJFF research programs vice president Alison Urkowitz said the progress achieved in addressing the unpredictable and debilitating OFF episodes associated with the variability of oral L-dopa administration was encouraging.
"We are hopeful that the Civitas therapy can play a key role in addressing this unmet need for Parkinson’s patients and are pleased to continue our support of CVT-301 as the therapy undergoes continued human clinical trials," Urkowitz added.